Authors
Loading...
Study demonstrates Trem2's role in the immunosuppressive niche of NASH-driven HCC, suggesting enhanced checkpoint therapy.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: